Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.

Authors: Daniela Sarnataro, Simona Pisanti, Antonietta Santoro, Patrizia Gazzerro, et al
Molecular Pharmacology, October 2006

The endocannabinoid system has been shown to modulate key cell-signaling pathways involved in cancer cell growth. In this study, we show that cannabinoid receptor type 1 (CB1) antagonist Rimonabant (SR141716) inhibited human breast cancer cell proliferation, being more effecti…

Cannabis use and expression of mania in the general population.

Authors: Cécile Henquet, Lydia Krabbendam, Ronde Graaf, Margreetten Have, Jimvan Os
Journal of Affective Disorders, October 2006

BACKGROUND: Cannabis use is common in patients with bipolar disorder, however little is known about cannabis as a risk factor for mania. In order to investigate the association between exposure to cannabis and subsequent development of manic symptoms whilst controlling for psy…

Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.

Authors: Alessia Ligresti, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, et al
Journal of Pharmacology and Experimental Therapeutics, September 2006

Delta(9)-Tetrahydrocannabinol (THC) exhibits antitumor effects on various cancer cell types, but its use in chemotherapy is limited by its psychotropic activity. We investigated the antitumor activities of other plant cannabinoids, i.e., cannabidiol, cannabigerol, cannabichrom…

Fatty acid amide hydrolase deficiency limits early pregnancy events.

Authors: Haibin Wang, Huirong Xie, Yong Guo, Hao Zhang, Toshifumi Takahashi, et al
Journal of Clinical Investigation, August 2006

Synchronized preimplantation embryo development and passage through the oviduct into the uterus are prerequisites for implantation, dysregulation of which often leads to pregnancy failure in women. Cannabinoid/endocannabinoid signaling via cannabinoid receptor CB1 is known to…

A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.

Authors: M. Guzmán, M. J. Duarte, C. Blázquez, J. Ravina, M. C. Rosa, I. Galve-Roperh, et al
British Journal of Cancer, 17 July 2006

Delta(9)-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumour growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested. However, the antitumoral effect of cannabinoids has never been tested in humans. Here we…

Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.

Authors: María M. Caffarel, David Sarrió, José Palacios, Manuel Guzmán, Cristina Sánchez
Cancer Research, 1 July 2006

It has been proposed that cannabinoids are involved in the control of cell fate. Thus, these compounds can modulate proliferation, differentiation, and survival in different manners depending on the cell type and its physiopathologic context. However, little is known about the…

Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.

Authors: Sachin Patel and Cecilia J. Hillard
Journal of Pharmacology and Experimental Therapeutics, July 2006

Extracts of Cannabis sativa have been used for their calming and sedative effects for centuries. Recent developments in drug discovery have suggested that modulation of neuronal endogenous cannabinoid signaling systems could represent a novel approach to the treatment of anxie…

Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia

Authors: Sebastian Walther, Richard Mahlberg, Uta Eichmann, Dieter Kunz
Psychopharmacology, May 2006

Nighttime agitation occurs frequently in patients with dementia and represents the number one burden on caregivers today. Current treatment options are few and limited due to substantial side effects. The aim of the study was to measure the effect of the cannabinoid dronabinol…

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Authors: A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães
Brazilian journal of medical and biological research, April 2006

A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent whi…

Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’.

Authors: Rachel E. Westfall, Patricia A. Janssen, Philippe Lucas, Rielle Capler
Complementary Therapies in Clinical Practice, February 2006

A majority of women experience some nausea and/or vomiting during pregnancy. This condition can range from mild nausea to extreme nausea and vomiting, with 1-2% of women suffering from the life-threatening condition hyperemesis gravidarum. Cannabis (Cannabis sativa) may be use…

A molecular link between the active component of marijuana and Alzheimer’s disease pathology.

Authors: Lisa M. Eubanks, Claude J. Rogers, George F. Koob, Arthur J. Olson, Tobin J. Dickerson, Kim D. Janda
Molecular Pharmaceutics, 2006

Alzheimer’s disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer’s disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease p…

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

Authors: D. R. Blake, P. Robson, M. Ho, R. W. Jubb, C. S. McCabe
Rheumatology, January 2006

OBJECTIVES: To assess the efficacy of a cannabis-based medicine (CBM) in the treatment of pain due to rheumatoid arthritis (RA). METHODS: We compared a CBM (Sativex) with placebo in a randomized, double-blind, parallel group study in 58 patients over 5 weeks of treatment. The…